Results 171 to 180 of about 10,435 (208)
Some of the next articles are maybe not open access.
Annals of Pharmacotherapy, 1993
Objective To introduce the reader to the use of a new agent, vigabatrin, in the treatment of refractory complex partial seizures. Clinical trials and pharmacokinetic data are reviewed, as well as neuropathology, adverse effects, drug interactions, and dosage guidelines.
openaire +3 more sources
Objective To introduce the reader to the use of a new agent, vigabatrin, in the treatment of refractory complex partial seizures. Clinical trials and pharmacokinetic data are reviewed, as well as neuropathology, adverse effects, drug interactions, and dosage guidelines.
openaire +3 more sources
Clinical Pharmacokinetics, 1992
Vigabatrin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is supplied as a racemic mixture, with the S(+) enantiomer possessing pharmacological activity. [R,S]-Vigabatrin plasma concentrations can be estimated using high-performance liquid chromatographic methods. Only gas chromatography-mass spectrometry
E, Rey, G, Pons, G, Olive
openaire +2 more sources
Vigabatrin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is supplied as a racemic mixture, with the S(+) enantiomer possessing pharmacological activity. [R,S]-Vigabatrin plasma concentrations can be estimated using high-performance liquid chromatographic methods. Only gas chromatography-mass spectrometry
E, Rey, G, Pons, G, Olive
openaire +2 more sources
Pharmacology & Toxicology, 1992
Abstract: Vigabatrin (gamma‐vinyl GABA) is a relatively new antiepileptic drug. Vigabatrin increases the concentration of gamma‐aminobutyric acid (GABA) in the brain by inhibiting the major GABA metabolizing enzyme, GABA transaminase. Controlled clinical trials have demonstrated an excellent antiepileptic effect of vigabatrin, especially in the ...
A, Sabers, L, Gram
openaire +2 more sources
Abstract: Vigabatrin (gamma‐vinyl GABA) is a relatively new antiepileptic drug. Vigabatrin increases the concentration of gamma‐aminobutyric acid (GABA) in the brain by inhibiting the major GABA metabolizing enzyme, GABA transaminase. Controlled clinical trials have demonstrated an excellent antiepileptic effect of vigabatrin, especially in the ...
A, Sabers, L, Gram
openaire +2 more sources
Epilepsia, 1995
Summary: γ‐Aminobutyric acid (GABA) was first proposed as a putative inhibitory neurotransmitter by Elliot and van Gelder in 1958. Since then, numerous efforts have been made to find ways to increase GABA at its receptor sites, based on the findings that decreased GABA results in convulsions in animals and that agents enhancing GABA‐mediated functions
openaire +2 more sources
Summary: γ‐Aminobutyric acid (GABA) was first proposed as a putative inhibitory neurotransmitter by Elliot and van Gelder in 1958. Since then, numerous efforts have been made to find ways to increase GABA at its receptor sites, based on the findings that decreased GABA results in convulsions in animals and that agents enhancing GABA‐mediated functions
openaire +2 more sources
The Neuropathology of Vigabatrin
Epilepsia, 1989Summary: Vigabatrin (gamma vinyl GABA, GVG), an enzyme‐activated, irreversible inhibitor of GABA transaminase, was administered orally to rats, dogs, and monkeys to observe toxicologic reactions. Myelin vacuolation of the brain was observed. The vacuolation was limited to myelinated tracts and resulted from separation of the myelin sheath at the ...
openaire +2 more sources